Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 19/20 | 0.79 |
| ▸ | BRAF | P15056 | 18/20 | 0.79 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.51 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL823606 | 0.88 | BRAF (1.00) | KDRBRAFRIPK1RIPK3 | |
| SCHEMBL13332052 | 0.84 | KDR (0.58) | KDRBRAFRIPK1RIPK3 | |
| SCHEMBL11995719 | 0.82 | BRAF (0.62) | KDRBRAFRIPK1RIPK3 | |
| SCHEMBL10268735 | 0.82 | KDR (0.70) | KDRBRAFRIPK1RIPK3 | |
| SCHEMBL11995455 | 0.81 | BRAF (0.55) | KDRBRAF | |
| SCHEMBL823678 | 0.80 | KDR (0.84) | KDRBRAFRIPK1RIPK3 | |
| SCHEMBL823549 | 0.78 | BRAF (0.82) | KDRBRAFRIPK1RIPK3 | |
| SCHEMBL823627 | 0.78 | BRAF (0.84) | KDRBRAFRIPK1RIPK3 | |
| SCHEMBL823531 | 0.77 | BRAF (0.81) | KDRBRAFRIPK1RIPK3 | |
| SCHEMBL823624 | 0.77 | BRAF (1.00) | KDRBRAFRIPK1RIPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214855-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214855-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | KDR 1130/4885BRAF 1/4885RIPK1 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.